Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn:
“mRNA vaccines as unplanned immunotherapy primers
SARS-CoV-2 mRNA vaccination triggers a type I IFN surge, activates APCs, and primes CD8⁺ T cells for tumor antigen recognition.
IFN-driven PD-L1 upregulation
Enhanced T-cell infiltration into ‘cold’ tumors
Reprogrammed immune microenvironment enabling ICI response
Clinically: COVID mRNA vaccine <100 days before IO exposure may increase OS in NSCLC and melanoma.”
Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
Authors: Adam J. Grippin, Christiano Marconi, Sage Copling, Nan Li, Chen Braun, Cole Woody, Elliana Young, Priti Gupta, Min Wang, Annette Wu, Seong Dong Jeong, Dhruvkumar Soni, Frances Weidert, Chao Xie, Eden Goldenberg, Andrew Kim, Chong Zhao, Anna DeVries, Paul Castillo, Rishabh Lohray, Michael K. Rooney, Benjamin R. Schrank, Yifan Wang, Yifan Ma, Enoch Chang, Ramez Kouzy, Kyle Dyson, Jordan Jafarnia, Nina Nariman, Gregory Gladish, Jacob New, Ada Argueta, Diana Amaya, Nagheme Thomas, Andria Doty, Joe Chen, Nikhil Copling, Gabriel Alatrash, Julie Simon, Alicia Bea Davies, William Dennis, Richard Liang, Jeff Lewis, Xiong Wei, Waree Rinsurongkawong, Ara A. Vaporciyan, Andrew Johns, D3CODE Team, Jack Lee, Ji-Hyun Lee, Ryan Sun, Padmanee Sharma, Hai Tran, Jianjun Zhang, Don L. Gibbons, Jennifer Wargo, Betty Y. S. Kim, John V. Heymach, Hector R. Mendez-Gomez, Wen Jiang, Elias J. Sayour, Steven H. Lin
Read the Full Article on Nature
More posts featuring Jean-Charles Soria.
